Original article
Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Astrid Pavlovskya,b, Juan Ignacio Garcia Altuvec, Amalia Ceruttid, Lorena Fiade, Nicolás Kurganskyf, Fernando Warleyg,
, Florencia Negri Arangurenh
a Centro de Hematologia Pavlovsky, Buenos Aires, Argentina
b FUNDALEU, Buenos Aires, Argentina
c Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina
d Sanatorio Británico de Rosario, Santa Fé, Argentina
e Hospital Italiano La Plata, Buenos Aires, Argentina
f DOCTUS, Buenos Aires, Argentina
g Hospital Italiano de Bueno Aires, Buenos Aires, Argentina
h Instituto Privado de Hematologia y Hemoterapia, Entre Ríos, Argentina
Lido
2160
Vezesque se leu este artigo
378
Total PDF
1782
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 10 | 102 | 17 | 119 |
| 2025 9 | 237 | 49 | 286 |
| 2025 8 | 160 | 44 | 204 |
| 2025 7 | 168 | 36 | 204 |
| 2025 6 | 104 | 26 | 130 |
| 2025 5 | 132 | 14 | 146 |
| 2025 4 | 78 | 18 | 96 |
| 2025 3 | 85 | 11 | 96 |
| 2025 2 | 80 | 26 | 106 |
| 2025 1 | 104 | 26 | 130 |
| 2024 12 | 88 | 20 | 108 |
| 2024 11 | 136 | 41 | 177 |
| 2024 10 | 284 | 38 | 322 |
| 2024 9 | 24 | 12 | 36 |
Mostrar tudo
